Australia
· Delayed Price · Currency is AUD Vitrafy Life Sciences Statistics
Total Valuation
Vitrafy Life Sciences has a market cap or net worth of AUD 105.35 million. The enterprise value is 122.23 million.
| Market Cap | 105.35M |
| Enterprise Value | 122.23M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Vitrafy Life Sciences has 63.85 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 63.85M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.50% |
| Owned by Institutions (%) | 0.95% |
| Float | 42.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 136.19 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.72 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.96 |
Financial Position
The company has a current ratio of 0.27
| Current Ratio | 0.27 |
| Quick Ratio | 0.26 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.43 |
| Interest Coverage | -1.02 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -90.89% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 1,689 |
| Profits Per Employee | -473,885 |
| Employee Count | 22 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 31.53 |
| Average Volume (20 Days) | 208,809 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vitrafy Life Sciences had revenue of AUD 37,166 and -10.43 million in losses. Loss per share was -3.40.
| Revenue | 37,166 |
| Gross Profit | 37,166 |
| Operating Income | -10.69M |
| Pretax Income | -10.43M |
| Net Income | -10.43M |
| EBITDA | -10.58M |
| EBIT | -10.69M |
| Loss Per Share | -3.40 |
Balance Sheet
The company has 6.45 million in cash and 23.33 million in debt, giving a net cash position of -16.88 million or -0.26 per share.
| Cash & Cash Equivalents | 6.45M |
| Total Debt | 23.33M |
| Net Cash | -16.88M |
| Net Cash Per Share | -0.26 |
| Equity (Book Value) | -24.60M |
| Book Value Per Share | -7.90 |
| Working Capital | -24.85M |
Cash Flow
In the last 12 months, operating cash flow was -6.79 million and capital expenditures -13,072, giving a free cash flow of -6.80 million.
| Operating Cash Flow | -6.79M |
| Capital Expenditures | -13,072 |
| Free Cash Flow | -6.80M |
| FCF Per Share | -0.11 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -28,767.86% |
| Pretax Margin | -28,051.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vitrafy Life Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -205.96% |
| FCF Yield | -6.46% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vitrafy Life Sciences has an Altman Z-Score of -11.05. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.05 |
| Piotroski F-Score | n/a |